HUTCHMED (China) (AIM:HCM) - Aktienkurs, Nachrichten und Analyse

HCM Aktienübersicht

HCM grundlegende Analyse
Schneeflocken-Punktzahl
Bewertung	2/6
Künftiges Wachstum	4/6
Vergangene Leistung	0/6
Finanzielle Gesundheit	4/6
Dividenden	0/6

Belohnungen

69.3% unter unserer Schätzung des beizulegenden Zeitwerts gehandelt

Prognostiziertes Gewinnwachstum 47.9% pro Jahr

Risikoanalyse

Bei unseren Risikoprüfungen wurden keine Risiken für HCM festgestellt.

HUTCHMED (China) Limited Wettbewerber

Dechra Pharmaceuticals

LSE:DPH

UK£4.4b

Hikma Pharmaceuticals

LSE:HIK

UK£4.0b

Indivior

LSE:INDV

UK£985.3m

Alliance Pharma

AIM:APH

UK£248.7m

Preisentwicklung & Leistung

Übersicht über alle Höchststände, Veränderungen und Kursrückgänge für HUTCHMED (China)
Historische Aktienkurse
Aktueller Aktienkurs	UK£2.65
52-Wochen-Hoch	UK£3.53
52-Wochen-Tief	UK£1.90
Beta	0.75
11 Monat Veränderung	-15.06%
3 Monate Veränderung	-4.33%
1 Jahr Veränderung	-11.07%
33 Jahre Veränderung	-47.00%
5 Jahre Veränderung	-27.20%
Veränderung seit IPO	957.88%

Aktuelle Nachrichten und Updates

HUTCHMED (China) Limited's (LON:HCM) 27% Jump Shows Its Popularity With Investors

Oct 19

Health Check: How Prudently Does HUTCHMED (China) (LON:HCM) Use Debt?

Sep 10

Recent updates

HUTCHMED (China) Limited's (LON:HCM) 27% Jump Shows Its Popularity With Investors

Oct 19

Health Check: How Prudently Does HUTCHMED (China) (LON:HCM) Use Debt?

Sep 10

Analysts Have Made A Financial Statement On HUTCHMED (China) Limited's (LON:HCM) Half-Year Report

Aug 02

HUTCHMED (China) Limited's (LON:HCM) P/S Still Appears To Be Reasonable

Jul 11

We Think HUTCHMED (China) (LON:HCM) Can Manage Its Debt With Ease

Apr 04

HUTCHMED (China) Limited's (LON:HCM) P/S Is Still On The Mark Following 31% Share Price Bounce

Mar 14

The HUTCHMED (China) Limited (LON:HCM) Analysts Have Been Trimming Their Sales Forecasts

Mar 01

With HUTCHMED (China) Limited (LON:HCM) It Looks Like You'll Get What You Pay For

Apr 19

Aktionärsrenditen

	HCM	GB Pharmaceuticals	GB Markt
7D	-4.0%	-2.2%	-0.3%
1Y	-11.1%	-3.2%	6.1%

Rendite im Vergleich zur Industrie: HCM unter dem Niveau der Branche UK Pharmaceuticals , die im vergangenen Jahr eine Rendite von -3.2% erzielte.

Rendite vs. Markt: HCM hinter dem Markt UK zurück, der im vergangenen Jahr eine Rendite von 6.1 erzielte.

Preisvolatilität

Is HCM's price volatile compared to industry and market?
HCM volatility
HCM Average Weekly Movement	6.0%
Pharmaceuticals Industry Average Movement	6.5%
Market Average Movement	4.7%
10% most volatile stocks in GB Market	10.3%
10% least volatile stocks in GB Market	2.6%

Stabiler Aktienkurs: HCM hat in den letzten 3 Monaten keine nennenswerten Preisschwankungen aufgewiesen.

Volatilität im Zeitverlauf: HCMDie wöchentliche Volatilität (6%) ist im vergangenen Jahr stabil geblieben.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
2000	1,970	Wei-Guo Su	www.hutch-med.com

HUTCHMED (China) Limited erforscht, entwickelt und vermarktet zusammen mit seinen Tochtergesellschaften zielgerichtete Therapeutika und Immuntherapien für Krebs und immunologische Erkrankungen in Hongkong und international. Das Unternehmen entwickelt Savolitinib zur Behandlung von nicht-kleinzelligem Lungenkrebs (NSCLC), papillärem Nierenzellkarzinom (RCC) und Magenkrebs (GC) sowie Fruquintinib, einen Hemmstoff für kolorektales Karzinom (CRC), Brustkrebs, Magenkrebs, mikrosatellitenstabiles Endometriumkarzinom (EMC), nicht-kleinzelliges Lungenkarzinom (NSCLC), papilläres Nierenzellkarzinom (RCC), Magen-Darm-Tumoren, Gebärmutterhalskrebs und solide Tumoren. Es entwickelt auch Surufatinib, das zur Behandlung von neuroendokrinen Tumoren der Bauchspeicheldrüse (NET), nicht-pankreatischen NET, neuroendokrinen Karzinomen, SCLC, Gallengangskrebs und soliden Tumoren eingesetzt wird, sowie Sovleplenib zur Behandlung von hämatologischen Krebserkrankungen und bestimmten chronischen Immunerkrankungen.

HUTCHMED (China) Limited's Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von HUTCHMED (China) im Vergleich zum Marktanteil des Unternehmens?
HCM grundlegende Statistiken
Marktanteil	UK£2.26b
Gewinn(TTM)	-UK£33.29m
Umsatz(TTM)	UK£484.51m

4.7x

Kurs-Umsatz-Verhältnis

-68.0x

Kurs-Gewinn-Verhältnis

Ist HCM zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
HCM Gewinn- und Verlustrechnung (TTM)
Einnahmen	US$610.81m
Kosten der Einnahmen	US$658.26m
Bruttogewinn	-US$47.45m
Sonstige Ausgaben	-US$5.48m
Umsatz	-US$41.97m

Zuletzt gemeldete Gewinne

Jun 30, 2024

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)	-0.049
Bruttomarge	-7.77%
Nettogewinnspanne	-6.87%
Schulden/Eigenkapital-Verhältnis	10.9%

Wie hat sich HCM auf lange Sicht entwickelt?

Historische Performance und Vergleiche

HCM Aktienübersicht

Belohnungen

Risikoanalyse

HUTCHMED (China) Limited Wettbewerber

LSE:DPH

UK£4.4b

LSE:HIK

UK£4.0b

LSE:INDV

UK£985.3m

AIM:APH

UK£248.7m

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

HUTCHMED (China) Limited's (LON:HCM) 27% Jump Shows Its Popularity With Investors

HUTCHMED (China) Limited Announces Positive High-Level Results from the SAVANNAH Phase II Trial

Health Check: How Prudently Does HUTCHMED (China) (LON:HCM) Use Debt?

Hutchmed (China) Limited Highlights Clinical Data to Be Presented at ESMO Congress 2024 and the 2024 World Conference of Lung Cancer

HUTCHMED Provides Update on Fruquintinib for Second-Line Gastric Cancer in China

First half 2024 earnings released: EPS: US$0.03 (vs US$0.20 in 1H 2023)

Recent updates

HUTCHMED (China) Limited's (LON:HCM) 27% Jump Shows Its Popularity With Investors

HUTCHMED (China) Limited Announces Positive High-Level Results from the SAVANNAH Phase II Trial

Health Check: How Prudently Does HUTCHMED (China) (LON:HCM) Use Debt?

Hutchmed (China) Limited Highlights Clinical Data to Be Presented at ESMO Congress 2024 and the 2024 World Conference of Lung Cancer

HUTCHMED Provides Update on Fruquintinib for Second-Line Gastric Cancer in China

First half 2024 earnings released: EPS: US$0.03 (vs US$0.20 in 1H 2023)

Analysts Have Made A Financial Statement On HUTCHMED (China) Limited's (LON:HCM) Half-Year Report

HUTCHMED (China) Limited Provides Revenue Guidance for the Year 2024

Investor sentiment improves as stock rises 16%

Consensus EPS estimates upgraded to US$0.11 loss

HUTCHMED (China) Limited's (LON:HCM) P/S Still Appears To Be Reasonable

HUTCHMED (China) Limited to Report First Half, 2024 Results on Jul 31, 2024

Hutchmed Highlights Publication of Phase Iii Eslim-01 Results in the Lancet Haematology

HUTCHMED (China) Limited Initiates Phase I Trial of Menin Inhibitor HMPL-506 in Patients with Hematological Malignancies in China

HUTCHMED (China) Limited Highlights Publication of Phase III FRUTIGA Results in Nature Medicine

HUTCHMED (China) Limited Highlights Presentations of New and Updated Data from Several Studies of Compounds Discovered by HUTCHMED At the Upcoming American Society of Clinical Oncology

HUTCHMED (China) Limited Announces Executive Changes

HUTCHMED (China) Limited Initiates the RAPMichael Registrational Phase III Trial of HMPL-306 for Patients with IDH1- and/or IDH2-Mutated Relapsed/Refractory Acute Myeloid Leukemia in China

HUTCHMED (China) Limited Initiates Phase II/III Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naive Pancreatic Ductal Adenocarcinoma in Collaboration with Hengrui

HUTCHMED (China) Limited Appoints Dr. Renu Bhatia as an Independent Non-Executive Director and a Member of Technical Committee, Effective May 13, 2024

HUTCHMED (China) Limited, Annual General Meeting, May 10, 2024

HUTCHMED (China) Limited Highlights Data to be Presented at AACR Congress 2024

We Think HUTCHMED (China) (LON:HCM) Can Manage Its Debt With Ease

HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status

HUTCHMED (China) Limited Announces Savolitinib sNDA Accepted in China for Treatment-Naive or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC

Hutchmed Initiates Registration Stage of the Eslim-02 Phase Ii/Iii Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China

HUTCHMED (China) Limited's (LON:HCM) P/S Is Still On The Mark Following 31% Share Price Bounce

Investor sentiment improves as stock rises 19%

The HUTCHMED (China) Limited (LON:HCM) Analysts Have Been Trimming Their Sales Forecasts

HUTCHMED (China) Limited Provides Revenue Guidance for the Year 2024

Full year 2023 earnings released: EPS: US$0.12 (vs US$0.43 loss in FY 2022)

Consensus revenue estimates decrease by 18%

Hutchmed (China) Limited Highlights Presentation of Phase III Data on Fruquintinib in Second-Line Gastric Cancer At Asco Plenary Series Session

HUTCHMED (China) Limited to Report Fiscal Year 2023 Results on Feb 28, 2024

HUTCHMED (China) Limited Receives Elunate® (Fruquintinib) Marketing Approval in Hong Kong for Treatment of Metastatic Colorectal Cancer

Consensus EPS estimates increase from loss to US$0.0102 profit

New minor risk - Share price stability

HUTCHMED (China) Limited Announces NDA Acceptance in China for Sovleplenib for the Treatment of Primary Immune Thrombocytopenia with Priority Review Status

Market Cool On HUTCHMED (China) Limited's (LON:HCM) Revenues

HUTCHMED (China) Limited Completes Enrollment of a Phase II/III Trial of Fruquintinib in Combination with Sintilimab for Advanced Renal Cell Carcinoma in China

Hutchmed (China) Limited Announces First in Human, Open-Label, Dose-Escalation Study of Erk1/2 Inhibitor Hmpl-295 in Patients with Advanced Solid Tumors

HUTCHMED (China) (LON:HCM) Is Using Debt Safely

Consensus EPS estimates increase from loss to US$0.0051 profit

HUTCHMED Announces that Takeda Receives U.S. FDA Approval of FRUZAQLA (fruquintinib) for Previously Treated Metastatic Colorectal Cancer

Consensus EPS estimates increase from loss to US$0.0016 profit

HUTCHMED (China) Limited Announces Submission of New Drug Application for Fruquintinib for Previously Treated Metastatic Colorectal Cancer in Japan

HUTCHMED (China) Limited Announces Presentation of Results from the Phase IIIb Trial of Savolitinib at the 2023 World Conference of Lung Cancer

Hutchmed (China) Limited Completes Patient Enrollment of a Bridging Study of Tazemetostat in Patients with Relapsed/Refractory Follicular Lymphoma in China

Consensus EPS estimates upgraded to US$0.0045 loss

New minor risk - Shareholder dilution

HUTCHMED Receives Breakthrough Therapy Designation in China for Savolitinib for Gastric Cancer

Does HUTCHMED (China) (LON:HCM) Have A Healthy Balance Sheet?

HUTCHMED (China) Limited Announces the Sovleplenib Phase III ESLIM-01 Study Met its Primary Endpoint in Primary Immune Thrombocytopenia in China

Key Executive exercised options to buy UK£6.7m worth of stock.

First half 2023 earnings released: EPS: US$0.20 (vs US$0.19 loss in 1H 2022)

HUTCHMED (China) Limited Receives Breakthrough Therapy Designation in China for Fruquintinib Combination with Sintilimab for Treatment of Advanced Endometrial Cancer, and Completes Enrollment of Registration Study

HUTCHMED (China) Limited Announces Changes to Board of Directors and Technical Committee

Hutchmed (China) Limited Initiates Phase I Study of Its Novel SHP2 Inhibitor HMPL-415 for Advanced Malignant Solid Tumors in China

Consensus estimates of losses per share improve by 42%

Erträge & Einnahmen